- Results of studies comparing Sanofi's Toujeo® and
insulin degludec
- Clinical implications for people living with diabetes
LAVAL, QC, Dec. 12, 2017 /CNW Telbec/ - Sanofi Canada
announces the results of recent studies comparing Sanofi's
Toujeo® (insulin glargine 300 Units/mL or Gla-300) to
insulin degludec 100 Units/mL (Deg-100). The results show positive
data that could lead to a better understanding of optimal treatment
for more than 3.4 million Canadians living with
diabetes.1 Each of these co-related studies concludes
that Toujeo® is a longer-acting insulin, provides a
constant glucose lowering effect over 24 hours with a once-daily
administration, low within day variability and clinical
benefits.2
The pharmacokinetic/pharmacodynamic (PK/PD) study comparing
Sanofi's Toujeo® and insulin degludec
The full results of this first PK/PD study with
Toujeo® and Deg-100 were presented on November 11, 2016, during the
16th Annual Diabetes Technology Meeting in
Bethesda, Maryland,
U.S.3 The results showed that the Toujeo®
PK/PD profile was flatter at a clinically relevant dose
(0.4 U/kg/day, the average dose used in worldwide clinical
practice)4 and more evenly distributed over
24 hours than the profile of insulin degludec for patients
with type 1 diabetes. The within-day fluctuation of metabolic
activity was 20% lower (p=0.047) for Toujeo® than
insulin degludec. An overall flat PK/PD profile and an evenly
distributed exposure over 24 hours were observed for
Toujeo® at both dose levels studied (0.4 and 0.6
U/kg/day).
"This is not the first time
Toujeo® is compared to other insulins, and consistently
showed positive results," said Dr. Hisham A.S. Mahmoud,
Medical Director at Sanofi Canada. "Toujeo® has already
demonstrated an improved PK/PD profile when compared to
insulin glargine 100 Units/mL (Gla-100). In a previous
CGM study (continuous glucose monitoring) comparing Gla-300 and
Gla-100, Toujeo® showed lower between-day variability
and lower within-day fluctuations, associated with a lower risk of
nocturnal confirmed (≤3 mmol/L) or severe
hypoglycemia."5
The results observed in the PK/PD study confirm that
Toujeo® has the potential to help people with diabetes
reach their targets with lower risk of hypoglycemia. Furthermore,
these results became the platform for the following ground
studies.
The LIGHTNING and Deliver D studies
The findings of two comparative real-world studies, LIGHTNING
and Deliver D, show that adults with diabetes who switched their
basal insulin therapy to Toujeo® or insulin degludec
experienced similar numbers of low blood sugar (hypoglycemia)
events. Patients also experienced similar reductions of average
blood sugar level (HbA1c) with both insulin treatments. These
results were presented on November 30
at the World Congress on Insulin Resistance, Diabetes &
Cardiovascular Disease in Los Angeles,
California, U.S.6,7
"The LIGHTNING and Deliver D
studies extend Sanofi's program of retrospective observational
analyses comparing Toujeo® with other basal insulins in
a real-world setting and reinforce the consistency of evidence
gathered across several patient populations," said Dr. Mahmoud. "In
this case, throughout these two studies, we compared
Toujeo® and insulin degludec based on two different
large U.S. databases of electronic medical records and claims using
a statistical technique in order to make the treatment groups
comparable. This approach minimizes observed sources of bias
typically found in simple observational studies."
The results of this comparison between Toujeo® and
insulin degludec from the LIGHTNING and Deliver D studies could be
reinforced, and thus, confirmed, with the results of the clinical
trial called BRIGHT, intended to be released in
2018.
The BRIGHT study
The BRIGHT study is the first head-to-head randomized clinical
trial comparing the efficacy and safety of Toujeo® and
insulin degludec 100 Units/mL.8
"We are proud to say that
Sanofi's Toujeo® met the primary study objective, which
was to determine if the effect of Toujeo® on blood sugar
levels (HbA1c) was similar to insulin degludec," mentioned Dr.
Riccardo Perfetti, Head of Global
Diabetes Medical Team, Sanofi.
Secondary objectives included the percentage of patients
experiencing adverse events, the total number of participants with
low blood sugar events during the study and the rate at which low
blood sugar events occurred. The study specifically followed 929
adults whose type 2 diabetes was previously uncontrolled on
non-insulin medication.
"Reducing the incidence of
hypoglycemic events without compromising blood sugar reduction is
an ongoing challenge for HCPs when managing their patients,
commented Dr. Alice Y.Y. Cheng,
Endocrinologist at Credit Valley Hospital and St. Michael's Hospital and Associate
Professor, Department of Medicine, University
of Toronto. "The most recently introduced long-acting
insulins have demonstrated benefits to adult patients with
diabetes. From the perspective of physicians and patients,
hypoglycemia remains a major limiting factor in effective blood
sugar management in diabetes."
The release of this new data contributes to the body of evidence
for positive patient outcomes with Toujeo® in people
with diabetes. The findings of the BRIGHT study are consistent with
previous pharmacological studies, including the EDITION Phase 3
clinical trial program.9,10,11,12
"All these results demonstrate
how Toujeo® can bring value to people
living with diabetes," claimed Niven
Al-Khoury, President at Sanofi Canada. "With over 100 years
of experience of working to understand and support the healthcare
needs of Canadians, being able to bring solutions is core to our
purpose."
Diabetes in Canada
Diabetes affects approximately 3.4 million Canadians, of
which type 2 diabetes accounts for 90% of
cases.13,14 It is estimated that 5.7 million
Canadians have prediabetes; this condition being characterized by
blood glucose levels above normal, but not high enough to be
diagnosed as diabetes. Fifty percent of individuals with
prediabetes will develop type 2 diabetes.15 Left
untreated, diabetes can lead to many serious complications, such as
heart disease, kidney disease, loss of vision and amputation of the
lower limbs.
About Toujeo®
Toujeo® is a
long-acting human insulin analog indicated to improve glycemic
control in adults with diabetes mellitus. Toujeo® has
been approved by the U.S. Food and Drug Administration (FDA), the
European Commission, Health Canada, the Therapeutic Goods
Administration in Australia, and
the MHLW in Japan (where its
approved brand name is Lantus® XR), and is under review
by other regulatory authorities around the world.
About Sanofi Diabetes and Cardiovascular
Diabetes and
cardiovascular disease affect millions of people worldwide, with
many managing the complex challenges of both. Building on its
portfolio evolution, heritage and expertise, Sanofi has implemented
a focused business unit dedicated to delivering innovative,
value-based medicines and integrated solutions in these therapeutic
areas. It is committed to a collaborative approach that involves
strategic alliances with professional and patient associations,
research institutions and leaders in healthcare and other
industries, with the goal of advancing scientific knowledge,
driving the convergence of science and technology, helping to
improve outcomes and inspiring an evolution in care.
About Sanofi www.sanofi.ca
Sanofi, a global
healthcare leader, discovers, develops and distributes therapeutic
solutions focused on patients' needs. Sanofi is organized into five
global business units: Diabetes and Cardiovascular, General
Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur, and
Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Together, Sanofi entities in Canada employ close to 1,900 people. In
2016, Sanofi companies invested $130 million in research and
development in Canada, creating
jobs, economic activity and opportunities throughout the
country.
Follow us on Twitter @SanofiCanada and on YouTube.
|
|
1http://www.diabetes.ca/how-you-can-help/advocate/why-federal-leadership-is-essential/diabetes-statistics-in-canada.
2Becker RH, Nowotny I, Teichert L, et al. "Low within-
and between-day variability in exposure to new insulin glargine 300
U/ml". Diabetes Obes Metab. 2015; 17(3): 261-7.
3Bailey T, et al. "Insulin Glargine 300 U/mL (Gla-300)
Provides More Stable and More Evenly Distributed Steady-state PK/PD
Profiles Compared with Insulin Degludec in Type 1 Diabetes". Poster
presented at Diabetes Technology Meeting, November 11,
2016.
4Data on file, Adelphi Real World Diabetes DSP XII,
2015.
5Bergenstal RM, et al. Diabetes Technol Ther
2015; 17(S1): 16 (Abstract 39).
6Zhou LF et al, "Hypoglycemia risk associated with basal
insulin use in type 2 diabetes (T2DM): The Lightning study", World
Congress on Insulin Resistance, Diabetes & Cardiovascular
Disease in Los Angeles, CA, U.S., November 30 – December 2,
2017.
7Blonde L et al, "Real-world evidence demonstrates
comparable clinical outcomes of switching from insulin glargine 100
U/mL (Gla-100) to insulin glargine 300 U/mL (Gla-300) vs insulin
degludec (IDeg) in patients with type 2 diabetes (T2D)", World
Congress on Insulin Resistance, Diabetes & Cardiovascular
Disease in Los Angeles, CA, U.S., November 30 – December 2,
2017.
8Sanofi, data on file: "Insulin glargine 300 U/mL vs
insulin degludec in insulin-naïve adults with T2DM: head-to-head
trial design and rationale", NCT02738151, November 2017.
9Riddle MC et al. Diabetes Care. 2014; 37(10):
2755-62, DOI: 10.2337/dc14-0991.
10Yki-Järvinen H, et al. Diabetes Care. 2014;
37(12): 3235-43, DOI: 10.2337/dc14-0990.
11Bolli GB, et al. Diabetes Obes Metab. 2015;
17(4): 386–94, DOI: 10.1111/dom.12438.
12Ritzel R, et al. Diabetes Obes Metab. 2015;
17(9): 859-67, DOI: 10.1111/dom.12485.
13Diabetes Canada, "Diabetes statistics in Canada":
http://www.diabetes.ca/how-you-can-help/advocate/why-federal-leadership-is-essential/diabetes-statistics-in-canada.
14Diabetes Québec, "Type 2 diabetes":
http://www.diabete.qc.ca/en/understand-diabetes/all-about-diabetes/types-of-diabetes/type-2-diabetes.
15Diabetes Canada, "Prediabetes":
https://www.diabetes.ca/about-diabetes/prediabetes.
|
SOURCE Sanofi Canada